Page 7 - Brain Communications News Today

News and commentary from the world of neurology and neuroscience

Contrary to earlier findings, new research shows there is no impact of erectile dysfunction on Alzheimers or dementia risk.

Phosphodiesterase-5 (PDE5) inhibitors seem not to be associated with a reduced risk for Alzheimer disease and related dementia.

Phosphodiesterase-5 (PDE5) inhibitors seem not to be associated with a reduced risk for Alzheimer disease and related dementia.

WEDNESDAY, Oct. 19, 2022 (HealthDay News) -- Phosphodiesterase-5 (PDE5) inhibitors seem not to be associated with a reduced risk for Alzheimer disease and related dementia, according to a study published online Oct. 4 in Brain Communications. Rishi J. Desai, Ph.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues compared the

Phosphodiesterase 5 inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to an NIH study.

Results from the National Institutes of Health's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study show that sildenafil (Viagra) and tadalafil (Cialis) may not be suitable candidates for treating dementia.

DREAM study findings conflict with other recent data

Neurological diseases often begin with an inflammatory process and the degradation of the so-called myelin layer, which surrounds the nerve fibers (axons) like a protective insulating layer.

Transparent peer review is a relative newcomer and not widely used at present, but it has grown in popularity and is becoming an increasingly popular choice. The question is—why? This blog post takes a closer look at the transparent peer review process, its rise in popularity, and the challenges journals, reviewers and editors face with this model.